Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals, Inc.

Overview
Date Founded

2011

Headquarters

620 MEMORIAL DRIVE SUITE 300 CAMBRIDGE MA 02139

Type of Company

Public

Employees (Worldwide)

76

Industries

Biotechnology

Company Description

Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyse unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. The firm focuses on developing treatments for cancer and immune mediated diseases and is building a pipeline of gene control medicines. The company was founded by Richard A. Young, Nathanael S. Gray and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.

Contact Data
Trying to get in touch with decision makers at Syros Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Chief Financial Officer

Chief Scientific Officer

Chief Medical Officer

Chief Legal & Administrative Officer

Chief Business Officer

Vice President, Chemistry & Early Development

Co-Founder

Scientific Founder

Investor

Board of Directors

Executive Chairman at ZappRx, Inc.

Co-Founder at Alnylam Pharmaceuticals, Inc.

Founder at Samsara Biocapital LLC

President & Chief Executive Officer at Dewpoint Therapeutics, Inc.

Professional at Tekla Healthcare Opportunities Fund

Chairman & Co-Founder at Vir Biotechnology, Inc.

President & Chief Executive Officer at Syros Pharmaceuticals, Inc.

Professional at Syros Pharmaceuticals, Inc.

Scientific Founder at Syros Pharmaceuticals, Inc.

Paths to Syros Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
Syros Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden

ARK Investment Management is a registered investment adviser and privately held investment firm, specializing in thematic investing. The firm is rooted in over thirty years of experience in identifying and investing in disruptive innovations that enable outsized growth as industries transform. Through its open source research process, ARK is able to identify companies that it believes are leading and benefiting from disruptive cross-sector forces and changing how the world works.

Details Hidden

Redmile Group invests primarily in U.S. and non-U.S. healthcare companies. While the partnerships and funds generally invest in public equities, these investtments may be in illiquid, publicly-quoted securities, investments may be made in illiquid, publicly-quoted securities. The partnerships or funds may invest in private companies and non-equity asset classes when Redmile Group believes such investments offer a superior risk-reward. The firm may also invest in fields related to healthcare where due diligence shows that the healthcare assets are the driving force behind value creation and may also invest in other sectors from time to time.While Redmile Group mainly invests public equities of healthcare companies, they gennerally have broad and flexible investment authority. To maintain flexibility and capitalize on investment opportunities as they arise, the Redmile Group isn't required to invest any particular percentage of managed portfolios in any particular type of investment or region, and the amount of the portfolios which is invested in any type of investment or which is weighted in different countries or different sectors can change at any time. As such, investments may at any time include long or short positions in U.S. or non-U.S. publicly traded or privately issued common stocks, preferred stocks, stock warrants and rights, bonds, notes or other debentures or debt participations, convertible bonds, convertible preference shares, fund interests, swaps, options (including options on stock market indices), futures contracts, commodities, forward contracts and other securities or financial instruments including those of investment companies.^

Details Hidden
Recent Transactions
Details Hidden

Syros Pharmaceuticals, Inc. issued . USD Common Stock and Warrants

Details Hidden

Syros Pharmaceuticals, Inc. issued . USD Common Stock

Details Hidden

Syros Pharmaceuticals, Inc. raised money in a private placement transaction

Insider Transactions
Details Hidden
Details Hidden
Transaction Advisors
Escrow Agent

Advised onSyros Pharmaceuticals, Inc. issued . USD Common Stock and Warrants

Underwriter

Advised onSyros Pharmaceuticals, Inc. issued . USD Common Stock and Warrants

Underwriter

Advised onSyros Pharmaceuticals, Inc. issued . USD Common Stock and Warrants

Professional

Advised onSyros Pharmaceuticals, Inc. issued . USD Common Stock

Underwriter

Advised onSyros Pharmaceuticals, Inc. issued . USD Common Stock

Managing Director Head of Healthcare Investment Banking, Health Care

Advised onSyros Pharmaceuticals, Inc. issued . USD Common Stock

Advisors & Consultants
Advisor

Professional at Blueprint Medicines Corp.

Clients

Incyte's vision is to become a leading drug discovery, development and commercial company by building a proprietary product pipeline of novel small molecule drugs for serious unmet medical needs. We have experienced management, discovery, clinical development and commercial teams. Our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference in health care, improve the lives of patients and build sustainable value for our shareholders. Our pipeline is focused on oncology and inflammation and includes compounds in various stages of development. Our lead product, JakafiĀ® (ruxolitinib), a JAK1 and JAK2 inhibitor, is currently approved in the United States for the treatment of intermediate or high-risk myelofibrosis (please see Full Prescribing Information and Important Safety Information for Jakafi) and is in development as a potential treatment for other cancers. We have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. Through strategic collaborations with Novartis and Eli Lilly, we are advancing the global development of two of our JAK1 and JAK2 inhibitor programs. Incyte's corporate headquarters is located in Wilmington, Delaware

Key Stats and Financials As of 2018
Market Capitalization
$231M
Total Enterprise Value
$81.6M
Earnings Per Share
$-1.91
Net Profit
$-62.3M
EBITDA
$-62.7M
EBITDAMargin
-3,058.15%
Total Debt
$31K
Total Equity
$78.6M
Enterprise Value Sales
39.81x
TEVNet Income
-1.31x
Debt TEV
0x
Three Year Compounded Annual Growth Rate Of Revenue
86.31%
Revenue
$2.05M
Investors
Details Hidden

Redmile Group invests primarily in U.S. and non-U.S. healthcare companies. While the partnerships and funds generally invest in public equities, these investtments may be in illiquid, publicly-quoted securities, investments may be made in illiquid, publicly-quoted securities. The partnerships or funds may invest in private companies and non-equity asset classes when Redmile Group believes such investments offer a superior risk-reward. The firm may also invest in fields related to healthcare where due diligence shows that the healthcare assets are the driving force behind value creation and may also invest in other sectors from time to time.While Redmile Group mainly invests public equities of healthcare companies, they gennerally have broad and flexible investment authority. To maintain flexibility and capitalize on investment opportunities as they arise, the Redmile Group isn't required to invest any particular percentage of managed portfolios in any particular type of investment or region, and the amount of the portfolios which is invested in any type of investment or which is weighted in different countries or different sectors can change at any time. As such, investments may at any time include long or short positions in U.S. or non-U.S. publicly traded or privately issued common stocks, preferred stocks, stock warrants and rights, bonds, notes or other debentures or debt participations, convertible bonds, convertible preference shares, fund interests, swaps, options (including options on stock market indices), futures contracts, commodities, forward contracts and other securities or financial instruments including those of investment companies.^

Details Hidden

Casdin Capital invests in early stage companies located in the US. The firm targets companies operating in the fields of life sciences and healthcare industry.

Details Hidden

Investor at Seagate Technology Plc

Suppliers
Dana-Farber Cancer Institute, Inc. IT Consulting & Services | Boston, MA

Since its founding in 1947, Dana-Farber has been committed to providing adults and children with cancer with the best treatment available today while developing tomorrow's cures through cutting-edge research. Read about our history, our breakthroughs, and the resources that help us support the health of our neighborhoods and communities.

RaQualia Pharma, Inc. Pharmaceuticals | Nagoya, AI

RaQualia Pharma, Inc. engages in a research and development of pharmaceuticals. Its medicines focus on pain, gastrointestinal, auto-immune diseases, inflammation, cancer, and Alzheimer's. Its products include Anidulafungin, Dalbavancin, Ziprasidone, 5-HT4 Partial Agonist, and 5-HT2B Antagonist. The company was founded on February 19, 2008 and is headquartered in Nagoya, Japan.

Ligand Pharmaceuticals, Inc. Medical Support Services | LA JOLLA , CA

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Celgene Corp. Pharmaceuticals

Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), myelofibrosis, small cell lung cancer and prostate cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies

Pfizer, Inc. Pharmaceuticals - New York, NY

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Syros Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Syros Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Syros Pharmaceuticals, Inc..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/syros-pharmaceuticals-inc-97186312
  • https://relationshipscience.com/organization/syros-pharmaceuticals-inc-97186312